Literature DB >> 6362875

Clinical safety and tolerance of mitoxantrone (Novantrone).

R J Crossley.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1983        PMID： 6362875     DOI： 10.1016/0305-7372(83)90019-1

Source DB:  PubMed          Journal:  Cancer Treat Rev        ISSN： 0305-7372            Impact factor:   12.111


× No keyword cloud information.
  10 in total

1.  Assessment of ventricular function by radionuclide angiography in patients receiving 4'-epidoxorubicin and mitoxantrone.

Authors:  D A Vorobiof; M Iturralde; G Falkson
Journal:  Cancer Chemother Pharmacol       Date:  1985       Impact factor: 3.333

2.  Survival following an extremely high-dose of mitoxantrone in a 73-year-old female with small cell bronchial carcinoma.

Authors:  R Koppensteiner; E Minar; L Marosi; H Ehringer
Journal:  J Cancer Res Clin Oncol       Date:  1988       Impact factor: 4.553

3.  Efficacy and Safety of Mitoxantrone Hydrochloride Injection for Tracing Axillary Sentinel Nodes in Breast Cancer: A Self-Controlled Clinical Trial.

Authors:  Dechuang Jiao; Benlong Yang; Jiajian Chen; Chunjian Wang; Lidan Jin; Wenhe Zhao; Xueqiang Gao; Haibo Wang; Jun Li; Haidong Zhao; Di Wu; Zhimin Fan; Shujun Wang; Zhenzhen Liu; Yongsheng Wang; Jiong Wu
Journal:  Front Oncol       Date:  2022-06-08       Impact factor: 5.738

4.  First-line combination chemotherapy with mitoxantrone and cyclophosphamide in advanced breast cancer.

Authors:  P Periti; G R della Cuna; F Pannuti; T Mazzei; P Preti; A Martoni; E Mini
Journal:  Invest New Drugs       Date:  1985       Impact factor: 3.850

5.  Mitoxantrone as a first-line treatment of advanced breast cancer.

Authors:  K Landys; S Borgstrom; T Andersson; H Noppa
Journal:  Invest New Drugs       Date:  1985       Impact factor: 3.850

6.  Lack of experimental vesicant activity for the anticancer agents cisplatin, melphalan, and mitoxantrone.

Authors:  R T Dorr; D S Alberts; M Soble
Journal:  Cancer Chemother Pharmacol       Date:  1986       Impact factor: 3.333

7.  Phase II study of vincristine, mitomycin-C and mitoxantrone in advanced breast cancer: a preliminary report of response and toxicity.

Authors:  T J Perren; G Blackledge; J J Mould; A D Chetiyawardana; M Morrison; A Hancock
Journal:  Invest New Drugs       Date:  1985       Impact factor: 3.850

8.  Quantitation of differential sensitivity of normal marrow myeloid progenitor cells to anthracene derivatives.

Authors:  D Bron; P Dodion; M Rozencweig; A Delforge; M A Mattelaer; Y Kenis; P Stryckmans
Journal:  Invest New Drugs       Date:  1986       Impact factor: 3.850

9.  Human central nervous system and plasma pharmacology of mitoxantrone.

Authors:  R M Green; D J Stewart; H Hugenholtz; M T Richard; M Thibault; V Montpetit
Journal:  J Neurooncol       Date:  1988       Impact factor: 4.130

10.  Phase II evaluation of mitoxantrone plus cis-platinum in patients with advanced breast cancer. A Southwest Oncology Group study.

Authors:  J O Atiba; S J Green; H E Hynes; C K Osborne; T P Miller; M Davidner
Journal:  Invest New Drugs       Date:  1994       Impact factor: 3.850
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.